Bastos-Oreiro, MarianaGutierrez, AntonioReguera, Juan LuísIacoboni, GloriaLópez-Corral, LucíaTerol, María JoséOrtíz-Maldonado, ValentínSanz, JaimeGuerra-Dominguez, LuisaBailen, RebecaMussetti, AlbertoAbrisqueta, PauHernani, RafaelLuzardo, HugoSancho, Juan-ManuelDelgado-Serrano, JavierSalar, AntonioGrande, CarlosBento, LeyreGonzález de Villambrosía, SoniaGarcía-Belmonte, DanielSureda, AnnaPérez-Martínez, AntonioBarba, PereKwon, MiMartín García-Sancho, Alejandro2023-05-032023-05-032022-07-12http://hdl.handle.net/10668/20580Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 months, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 months, penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/CAR-T cell therapyreal world evidence (RWE)refractory aggressive B cell lymphomascholar-1 criteriastandard of care (SOC)Antigens, CD19HumansLymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenRetrospective StudiesT-Lymphocytesresearch article35911769open access10.3389/fimmu.2022.8557301664-3224PMC9336530https://www.frontiersin.org/articles/10.3389/fimmu.2022.855730/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336530/pdf